Sponsor:
BIOHENG THERAPEUTICS US LLC
Code:
NCT07070219
Conditions
Acute Lymphocytic Leukemia Refractory
Lymphoma, Lymphoblastic
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
CTD402 CAR T Cell Injection
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-19. This information was provided to ClinicalTrials.gov by BIOHENG THERAPEUTICS US LLC on 2025-10-14.